Drugdiscovery >> Drug Development >> News
4796
Views
Development in curing deadly type of breast cancer - drugdiscovery.com
Development in curing deadly type of breast cancer - drugdiscovery.com


Scientists of Weill Cornell Medical College have made a progress in finding cure for triple-negative breast cancer. The techniqe sounds strange, but is very effective: scientists use the patients own tumor cells, transplantes into mice to get them modified.
Read More >>


Tags: triple negative breast-cancer, genetics, tumor, breast cancer, tumor cells. - March 25, 2014
Related Articles
5161
Views
The development of preventive breast cancer vaccine The development of preventive breast cancer vaccine
Shield Biotech is a new company, created by Cleveland Clinic Innovations, that will complete preclinical development of the vaccine and move it to first-in-human clinical trials. Read More >>

Tags: breast cancer, vaccine, preventive, development, Cleveland Clinic Innovations

5001
Views
Scientist see a new hope in breast cancer treatments Scientist see a new hope in breast cancer treatments
According to scientists "personal drugs" can be a new way in breast-cancer treatment. they found that almost all of the aggressively growing cells are from the sam genetic type - and via this discover Read More >>

Tags: treatment, drug, drug discovery, breast cancer, breast cancer drug

3449
Views
The touching site of drug development The touching site of drug development
the reporter of Wall street Journal followed the journey of 4 families, whose children suffered from a rare disease. Niemann-Pick Type C disease has no cure yet, but an enormous effort were made towar Read More >>

Tags: Niemann-Pick Type C disease, drug development, report, rare disease, children with rare disease

16793
Views
An experimental breast cancer drug shows potential for treating lung cancer An experimental breast cancer drug shows potential for treating lung cancer
Experimental drugs called PARP inhibitors, which are already in clinical trials for treating breast and ovarian cancer, could also be a promising treatment for a subset of non-small-cell lung cancer Read More >>

Tags: experimental drug, breast cancer, lung cancer, non small cell lung cancer, PARP inhibitors,clinical trial, olaparib, small-cell lung cancer, veliparib

3741
Views
New hope in curing gialoblastoma New hope in curing gialoblastoma
Scientist examined gialoblastoma and found some inactivated cells which would destroy the tumour-cells. Tests on mice sohw, that if these cells are reactivated, the patients can live 2-3 times longer. Read More >>

Tags: gialoblastoma, brain cancer, research

5534
Views
The development of vaccine treatments for renal cell cancer and melanoma The development of vaccine treatments for renal cell cancer and melanoma
IMA901 cancer vaccine is currently in Phase 3 trials as a first-line treatment of metastatic renal cell cancer. Another vaccine for renal cell carcinoma, AGS-003 is currently at the same stage of deve Read More >>

Tags: cancer, vaccine, renal cell cancer, melanoma, clinical trials, development

4411
Views
Entry of new Type 2 Diabestes drug in the UK: Only one per day Entry of new Type 2 Diabestes drug in the UK: Only one per day
The new drug, Lixisenatide, with the brand name Lyxumia is cheaper than existing drugs and it can be self administered daily once with an injection pen. It will work on GLP-1 hormone and control insu Read More >>

Tags: Type 2 Diabetes, Lyxumia, Lixisenatide

2769
Views
Breakthrough in cancer research – Rational, personalized combination therapy against cancer driver genes Breakthrough in cancer research – Rational, personalized combination therapy against cancer driver genes
There is a breakthrough now in cancer research and therapy providing personalized targeted drug combinations for cancer patients to treat the disease and overcome primary and secondary resistance due Read More >>

Tags: cancer drugs, cancer research, DriverHit Library, drug development, genes

4265
Views
The identification of drug candidate for neurofibromatosis type 2 The identification of drug candidate for neurofibromatosis type 2
The drug candidate, FRAX97, originally developed to treat neurodegenerative diseases, slows the growth of tumors in animal models of neurofibromatosis type 2, an inherited type of cancer which affects Read More >>

Tags: neurofibromatosis, neurofibromatosis type 2, tumor, auditory nerve, drug candidate, new drug, research

4238
Views
Lilly's drug and Kadcyla were both turned down Lilly's drug and Kadcyla were both turned down
Kadcyla unaffordable for NHS, Lilly's Alimta also turned down in NSCLC maintenance setting, but BI's Giotrif is approved for NSCLC subset Read More >>

Tags: pharmatimes,pharma,news,pemetrexed,NICE,NHS,Giotrif,Roche ,Kadcyla,Alimta,breast cancer,NSCLC,afatinib,EGFR-TK,trastuzumab emtansine,CDF,

MOST VIEWED
HOME | ABOUT | PRIVACY POLICY | TERMS & CONDITIONS | ADVERTISE | CONTACT
All rights reserved drugdiscovery.com 2013